Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.verified

ALDX

Price:

$5.18

Market Cap:

$307.80M

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for ...[Read more]

Industry

Biotechnology

IPO Date

2014-05-02

Stock Exchange

NASDAQ

Ticker

ALDX

The Enterprise Value as of November 2024 (TTM) for Aldeyra Therapeutics, Inc. (ALDX) is 292.41M

According to Aldeyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 292.41M. This represents a change of 71.33% compared to the average of 170.67M of the last 4 quarters.

Aldeyra Therapeutics, Inc. (ALDX) Historical Enterprise Value (quarterly & annually)

How has ALDX Enterprise Value performed in the past?

The mean historical Enterprise Value of Aldeyra Therapeutics, Inc. over the last ten years is 99.62M. The current 292.41M Enterprise Value has changed 29.25% with respect to the historical average. Over the past ten years (40 quarters), ALDX's Enterprise Value was at its highest in in the March 2023 quarter at 434.88M. The Enterprise Value was at its lowest in in the December 2021 quarter at 18.14M.

Quarterly (TTM)
Annual

Average

99.62M

Median

84.65M

Minimum

2.24M

Maximum

278.17M

Aldeyra Therapeutics, Inc. (ALDX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aldeyra Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 12.34%

Maximum Annual Enterprise Value = 278.17M

Minimum Annual Increase = -98.69%

Minimum Annual Enterprise Value = 2.24M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202379.72M-71.34%
2022278.17M12.34%
20212.24M-98.69%
2020170.48M33.34%
2019127.85M-3.61%
2018132.63M48.06%
201789.58M79.04%
201650.04M10.75%
201545.18M122.63%
201420.29M5.43%

Aldeyra Therapeutics, Inc. (ALDX) Average Enterprise Value

How has ALDX Enterprise Value performed in the past?

The current Enterprise Value of Aldeyra Therapeutics, Inc. (ALDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

120.04M

5-year avg

131.69M

10-year avg

99.62M

Aldeyra Therapeutics, Inc. (ALDX) Enterprise Value vs. Peers

How is ALDX’s Enterprise Value compared to its peers?

Aldeyra Therapeutics, Inc.’s Enterprise Value is less than Tarsus Pharmaceuticals, Inc. (1.65B), greater than LianBio (-66141903.00), less than Travere Therapeutics, Inc. (1.78B), greater than Eton Pharmaceuticals, Inc. (202.92M), less than Viridian Therapeutics, Inc. (1.66B), less than Terns Pharmaceuticals, Inc. (508.25M), less than Structure Therapeutics Inc. (1.90B), less than Blueprint Medicines Corporation (6.13B), less than 89bio, Inc. (799.03M), greater than X4 Pharmaceuticals, Inc. (20.60M), less than Inozyme Pharma, Inc. (308.76M), less than Day One Biopharmaceuticals, Inc. (1.07B), greater than HOOKIPA Pharma Inc. (-26926933.00), less than Phathom Pharmaceuticals, Inc. (1.52B), greater than Lyra Therapeutics, Inc. (22.05M), less than Cullinan Oncology, Inc. (810.70M), greater than BioLineRx Ltd. (59.04M), less than Ardelyx, Inc. (1.45B), less than Lexicon Pharmaceuticals, Inc. (505.66M), greater than Seres Therapeutics, Inc. (278.81M), less than ImmunityBio, Inc. (4.49B),

Build a custom stock screener for Aldeyra Therapeutics, Inc. (ALDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aldeyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aldeyra Therapeutics, Inc. (ALDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aldeyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aldeyra Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?

What is the 3-year average Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?

What is the 5-year average Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?

How does the current Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX) compare to its historical average?